Fibrocell Technologies, Inc.
BiotechFibrocell Technologies, Inc. is a biotechnology company with 1 FDA-approved products.
Fibrocell Technologies, Inc.'s Key Drugs
Fibrocell Technologies, Inc.'s core commercial portfolio centers on Laviv — its most strategically important drugs approved in the last 15 years.
Fibrocell Technologies, Inc.'s Recent FDA Approvals
New NDA/BLA approvals for Fibrocell Technologies, Inc. over the last two years — novel drugs only, excluding generics and label supplements.
Fibrocell Technologies, Inc.'s Therapeutic Areas
Disease areas where Fibrocell Technologies, Inc. has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
Fibrocell Technologies, Inc. Pipeline Snapshot
Active clinical trials for Fibrocell Technologies, Inc. across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Laviv leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2011-06-20
- Latest
- 2011-06-20
- Applications
- 1